In our experience, there are at least three key factors pharmaceutical and life sciences companies should consider as they select and engage with clinical data providers.
Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.
In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drug makers.
Most life sciences execs agree that their companies — even early adopters of AI — still need to make significant changes to leverage AI properly. Here's how to get started (or keep forging ahead).
A large pharmaceutical company was looking to validate its list of 100+ U.S. sites for a chronic auto-immune disease study. Leveraging medical claims data, a site-level analysis was conducted to identify relevant patients meeting the trial’s I/E criteria.
Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more